22 Baseline Glu elevations normalized with treatment but there were no changes in NAA. However, the Glu normalization did not correlate with symptom

improvement. These results are consistent with a dopamine D2 modulation of striatal hypeglutamalergia. Consistently, Goto et al23 reported similar Glx prefrontal reductions following 6 months of antipsychotic treatment. Experimental agent www.selleckchem.com/products/Enzastaurin.html studies Few studies have used 1H-MRS to examine neurochemical effects of non-dopamine Inhibitors,research,lifescience,medical D2 blockers for potential applications in schizophrenia. Jarkog et al24 recently examined the effect of adjunct davunetide (a neurotrophic peptide) for 12 weeks in schizophrenia. Higher-dose davunetide (30 mg/day) resulted in marginal prefrontal NAA and Cho increases, Inhibitors,research,lifescience,medical suggesting a neuroprotective effect. However, there were no correlations with symptoms or cognitive measures. selleck kinase inhibitor Glycine has been examined for the treatment of negative

symptoms, and an 1H-MRS sequence is sensitive enough to detect brain elevations in the context of oral administration in healthy volunteers.25 Future studies may examine the glycine spectra in clinically treated populations. Finally, in a knockout mouse model with reduced glutathione, N-acetyl cysteine administration during gestation was found to revert abnormally Inhibitors,research,lifescience,medical elevated prepuberal brain Gin and Gln/Glu.26 This is somewhat consistent with a studydocumenting effects of N-acetyi cysteine (NAC) on negative symptoms.27 However, there have been no reports examining the effects of NAC on 1H-MRS measures in schizophrenia. Bipolar disorder Disease-related findings The Kraguljac et Inhibitors,research,lifescience,medical al2 meta-analysis reported

NAA reductions only in basal ganglia and elevations in dorso-lateral prefrontal cortex (however, heterogeneity of studies was high for the latter). There were no differences in Cre or Cho. In another meta-analysis28 Glx was found to be elevated, mainly in the frontal region, regardless of medication or clinical state.29 One study reported reduced occipital GABA.30 These results suggest increased glutamatergic indices in bipolar disorder, without the more widespread neuronal dysfunction (reduced NAA) found in schizophrenia. Inhibitors,research,lifescience,medical Treatment-related studies Some studies have used 1H-MRS in bipolar mania to evaluate correlates of treatment with lithium, other mood stabilizers, and antipsychotic agents. Lithium Cross-sectional studies suggested that lithium therapyincreases NAA31,32 in bipolar patients. However, longitudinal human studies33,34 as well GSK-3 as a rodent study35 failed to detect NAA changes. Conversely, reductions in Glx have been reported in longitudinal human33 and rat35 studies with lithium, consistent with an improvement of Glx in bipolar disorder. However, documentation of a relationship between Glx reductions and symptom improvement is lacking. Additionally, lithium induced myoinositol reductions which did not relate to changes in mood,36 but another longitudinal study found increases in this metabolite.